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Sir
In your supplemental issue for volume 84, dated April 2001, Egrie
and Browne (2001) reported a compilation of studies on the char-
acterisation of novel erythropoiesis stimulating protein (NESP).
NESP is a mutated form of the native hormone, erythropoietin.
In NESP, ﬁve amino acids have been mutated (i.e., Ala30Asn,
His 32Thr, Pro87Val, Trp88Asn and Pro90Thr) in order to incor-
porate two additional N-linked carbohydrate chains for a total of
ﬁve carbohydrate moieties. In contrast, human erythropoietin as
well as its recombinant form, r-HuEPO, has three N-linked carbo-
hydrate chains. For comparative studies with NESP, Egrie and
Browne (2001) used r-HuEPO.
In this report, it is shown that by increasing the sialic acid resi-
due content of erythropoietin, the serum half life of the
recombinant molecule, NESP, was approximately three-fold longer
than that of r-HuEPO, primarily due to a prolonged clearance
from the circulation. However, features in common between the
two molecules are their nonlinear pharmacokinetics and pharma-
codynamics. An increase in dose is required for both molecules
when switching from a thrice-weekly (TIW) to a once-weekly
(QW) regimen. For example, NESP 1.25 mgk g
71 TIW (total
weekly dose: 3.75 mgk g
71) had to be increased four-fold to
15 mgk g
71 QW in order to achieve a nearly identical biological
response. For r-HuEPO, the authors claimed that a 15-fold increase
in the weekly dose of r-HuEPO was needed to switch from the
TIW to the QW regimen in the animal model tested. In light of
these ﬁndings, the authors continue to state that NESP has a
‘greater’ efﬁciency than r-HuEPO due to its ‘greater’ potency. Since
pharmacodynamic responses depend on dose, route of administra-
tion, and dosing regimen, it is apparent that additional
experimental data would be needed to substantiate a statement
regarding the ‘greater’ potency of NESP. In the animal model
tested, the data presented were derived from doses administered
intravenously, and no comparison was made with alternative deliv-
ery routes (e.g., subcutaneous). Moreover, these results in animals
appear to be of no consequence, since in humans, a similar biolo-
gical response for NESP was achieved with an optimal weekly dose
administered either once or divided into three doses (Macdougall,
1998). Similarly for r-HuEPO, 150 IU kg
71 TIW (total weekly
dose: 450 IU kg
71) and 600 IU kg
71 QW (approximately
40000 IU QW) regimens have been shown to produce a similar
pharmacodynamic response in the rise of haemoglobin (Cheung
et al, 1998). Thus, with the major differences in the erythropoiesis
and red blood cell lifespan between rodents and humans, one must
be cautious in extrapolating the data of in vivo biologic activity
based upon small animal models to humans.
It is also important to note that potency cannot be equated
with efﬁcacy. In another set of experiments, efﬁcacy was investi-
gated using equimolar doses (i.e., equivalent peptide mass) of r-
HuEPO, an erythropoietin analogue containing four N-linked
carbohydrates, and NESP. For example, the results of one of these
experiments showed that the haematocrit in mice increased by
22.8+2.3, 28.1+6.8, and 33.9+3.4 points, respectively. The
authors concluded that since the bulkiness of NESP lowers its afﬁ-
nity for the erythropoietin receptor, clearance (i.e., in vivo
potency) was the primary determinant for the higher magnitude
in efﬁcacy. With due respect to the authors, your readership is
misled by the assessment that NESP has an enhanced efﬁcacy
compared with r-HuEPO or the four N-linked chain analogue.
It appears that the authors are remiss in not considering that
an equimolar dose is not equivalent to an equipotent dose, and
thus conclusions regarding efﬁcacy cannot be made. The use of
equipotent doses would have been the appropriate experimental
design for testing efﬁcacy.
NESP is a product of only ﬁve point mutations, and the reader-
ship should be aware that some of the point mutations introduced
into the erythropoietin molecule for the consensus sequences of
additional carbohydrate moieties are nonconservative, especially
those at residues 87, 88, and 90. In the native molecule, these resi-
dues contain ring structures. Since the predicted structure of
endogenous erythropoietin is comprised of four a helices with a
common secondary structural motif and bundled into a tertiary
fold (Wrighton et al, 1996), these three bulky and more rigid resi-
dues potentially promote major turns in the polypeptide backbone.
Thus in the NESP molecule, replacing these bulky residues with
smaller and/or less rigid amino acids, the structure may change
not only with additional carbohydrate moieties but also with the
structural motif of the polypeptide backbone. As noted by the
authors, the carbohydrate moieties may mask the point mutations
themselves from the immune system; however, changes in second-
ary structure downstream from the point mutations cannot be
ruled out. *Correspondence: H Malonne; E-mail: hugues.malonne@ulb.ac.be
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the pharmacokinetic differences in half life and clearance between
NESP and r-HuEPO (Macdougall, 1999). However, studies in
humans using NESP have shown an efﬁcacy proﬁle that is compar-
able to r-HuEPO (Coyne et al, 2000; Nissenson et al, 2000;
Locatelli et al, 2001). These studies reinforce the fact that results
garnered from animal models are not necessarily indicative of what
is to be ascertained in humans.
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Sir
The development of darbepoetin alfa (NESP, ARANESP
TM) was an
outgrowth of basic research directed towards elucidating those
structural features that control the in vivo biological activity of
erythropoietin (EPO). As described in our study, this research
demonstrated that serum clearance is the primary determinant of
EPO in vivo biological activity, and that serum clearance can be
manipulated by changing the proportion of sialic acid-containing
carbohydrate. Molecules having a higher proportion of sialic
acid-containing carbohydrate have a longer serum half-life and
thereby a higher in vivo biological activity. These principles,
gleaned from natural sequence EPO, were applied and extended
to speciﬁcally engineer a new molecule, NESP. Our review article
(Egrie and Browne, 2001) summarized the basic research leading
to the design of NESP and summarized the results of comparative
pharmacodynamic studies of NESP and rHuEPO.
As we stated in our article, the relative potency of NESP and
rHuEPO were determined in a normal mouse animal model in
which both molecules produced dose-dependent increases in
hematocrit. These studies were performed using three different
routes of administration and three different dosing frequencies.
For each route, frequency, and test article, multiple doses were
tested which covered the entire dose response range. The results
of these experiments were used to construct relative potency
plots (log dose response curves). The relative potency was then
determined as the ratio of equieffective doses of each from their
respective graded dose–response relations (Tallarida and Murray,
1987). When data from all studies were combined (nine experi-
ments using 1185 animals), NESP was determined to be 3.6-fold
more potent than rHuEPO for each route of administration
when given three times per week. That is, it takes 3.6-fold more
rHuEPO to obtain the same biological response as NESP. As a
corollary, when equimolar doses of NESP and rHuEPO are
compared, rHuEPO produces a lower biological response, as is
illustrated in our Figure 5 and noted in paragraph 3 of Dr *Correspondence: J Egrie; E-mail: joanne@amgen.com
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